Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?
Yıl: 2021 Cilt: 49 Sayı: 4 Sayfa Aralığı: 254 - 256 Metin Dili: İngilizce DOI: 10.5543/tkda.2021.94055 İndeks Tarihi: 29-01-2022
Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?
Öz: -
Anahtar Kelime: Türkiye’deki varfarin kullanıcılarında terapötik aralıktaki süre: Geri ödemede kesin kriterler belirlemek için yeterli veri var mı?
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
- 1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. [Crossref]
- 2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. [Crossref]
- 3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. [Crossref]
- 4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104. [Crossref]
- 5. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. [Crossref]
- 6. Ertas F, Kaya H, Kaya Z, Bulur S, Kose N, Gul M, et al. Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. Turk Kardiyol Dern Ars 2013;41:99-104. [Crossref]
- 7. Ertas F, Kaya H, Ozhan H. Epidemiology of atrial fibrillation in Turkey: preliminary results in the multicenter AFTER study. Author reply. Turk Kardiyol Dern Ars 2013;41:370. [Crossref]
- 8. Aksan G, Soylu K, Demircan S, Aksoy O, Yanik A, Gedikli O, et al. Oral anticoagulant therapy and clinical outcomes in patients with atrial fibrillation: a pilot study from a single center registry. Blood Coagul Fibrinolysis 2014;25:688-94. [Crossref]
- 9. Celik A, Izci S, Kobat MA, Ates AH, Cakmak A, Cakilli Y, et al. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol 2016;16:595-600. [Crossref]
- 10. Atas H, Sahin AA, Barutcu Atas D, Sunbul M, Kepez A, Agirbasli M. Potential causes and implications of low target therapeutic ratio in warfarin-treated patients for thrombosis prophylaxis: a single-center experience. Clin Appl Thromb Hemost 2018;24:536-41. [Crossref]
- 11. Varim P, Varim C, Ergenc H, Uyanik M, Yaylaci S, Vatan M, et al. Assessment of warfarin treatment efficacy by means; of using coagulation test results within the therapeutic range. Georgian Med News 2016;255:62-6.
- 12. Alisir M, Kecebi M, Besli F, Caliskan S, Gungoren F, Ahmet Yildirim A, et al. The rates of effective INR levels and the relationship with etiology in patients with warfarin treatment. Turkiye Klinikleri J Med Sci;33:868-73. [Crossref]
- 13. Erdemoğlu E, Uzunlulu M, Oğuz A, Köstek O, Telci-Çaklılı O. Frequency of coagulation test results being in the therapeutic range in patients using warfarin treatment. Medeniyet Medical Journal 2015;30:105-9.
- 14. Ertaş F KH, Atılgan ZA, Elbey MA, Aydin M, Akil MA. Predictors of warfarin use in patients with non-valvular atrial fibrillation who presented to the cardiology outpatient clinic of a tertiary hospital in Turkey: an observational study. Turk J Med Sci 2012;42:1172-9.
- 15. Karacaglar E, Atar I, Yetis B, Corut H, Ersoy B, Yilmaz K, et al. [The frequency of embolic risk factors and adequacy of anti-embolic treatment in patients with atrial fibrillation: a single tertiary center experience]. Anadolu Kardiyol Derg 2012;12:384-90. [Crossref]
- 16. Kilic S, Soner Kemal H, Yuce EI, Simsek E, Yagmur B, Memisoglu Akgul N, et al. Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. Anatol J Cardiol 2017;18:328-33. [Crossref]
- 17. Turk UO, Tuncer E, Alioglu E, Yuksel K, Pekel N, Ozpelit E, et al. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry. Cardiol J 2015;22:567-75. [Crossref]
- 18. Ertas F, Duygu H, Acet H, Eren NK, Nazli C, Ergene AO. [Oral anticoagulant use in patients with atrial fibrillation]. Turk Kardiyol Dern Ars 2009;37:161-7.
- 19. Kilic S, Celik A, Cakmak HA, Afsin A, Tekkesin AI, Aciksari G, et al. The time in therapeutic range and bleeding complications of warfarin in different geographic regions of Turkey: a subgroup analysis of WARFARIN-TR study. Balkan Med J 2017;34:349-55. [Crossref]
| APA | TOPCUOGLU M, Arsava E (2021). Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. , 254 - 256. 10.5543/tkda.2021.94055 |
| Chicago | TOPCUOGLU MEHMET,Arsava Ethem Murat Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. (2021): 254 - 256. 10.5543/tkda.2021.94055 |
| MLA | TOPCUOGLU MEHMET,Arsava Ethem Murat Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. , 2021, ss.254 - 256. 10.5543/tkda.2021.94055 |
| AMA | TOPCUOGLU M,Arsava E Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. . 2021; 254 - 256. 10.5543/tkda.2021.94055 |
| Vancouver | TOPCUOGLU M,Arsava E Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. . 2021; 254 - 256. 10.5543/tkda.2021.94055 |
| IEEE | TOPCUOGLU M,Arsava E "Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?." , ss.254 - 256, 2021. 10.5543/tkda.2021.94055 |
| ISNAD | TOPCUOGLU, MEHMET - Arsava, Ethem Murat. "Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?". (2021), 254-256. https://doi.org/10.5543/tkda.2021.94055 |
| APA | TOPCUOGLU M, Arsava E (2021). Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. Türk Kardiyoloji Derneği Arşivi, 49(4), 254 - 256. 10.5543/tkda.2021.94055 |
| Chicago | TOPCUOGLU MEHMET,Arsava Ethem Murat Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. Türk Kardiyoloji Derneği Arşivi 49, no.4 (2021): 254 - 256. 10.5543/tkda.2021.94055 |
| MLA | TOPCUOGLU MEHMET,Arsava Ethem Murat Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. Türk Kardiyoloji Derneği Arşivi, vol.49, no.4, 2021, ss.254 - 256. 10.5543/tkda.2021.94055 |
| AMA | TOPCUOGLU M,Arsava E Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. Türk Kardiyoloji Derneği Arşivi. 2021; 49(4): 254 - 256. 10.5543/tkda.2021.94055 |
| Vancouver | TOPCUOGLU M,Arsava E Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?. Türk Kardiyoloji Derneği Arşivi. 2021; 49(4): 254 - 256. 10.5543/tkda.2021.94055 |
| IEEE | TOPCUOGLU M,Arsava E "Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?." Türk Kardiyoloji Derneği Arşivi, 49, ss.254 - 256, 2021. 10.5543/tkda.2021.94055 |
| ISNAD | TOPCUOGLU, MEHMET - Arsava, Ethem Murat. "Time in therapeutic range among warfarin users in Turkey: Are there enough data to set definitive criteria for reimbursement?". Türk Kardiyoloji Derneği Arşivi 49/4 (2021), 254-256. https://doi.org/10.5543/tkda.2021.94055 |
